Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?

International journal of molecular sciences - 5 Jul 2021

Vuletić Vladimira, Rački Valentino, Papić Eliša, Peterlin Borut

Abstract excerpt

BACKGROUND: Parkinson's disease (PD) is the second most frequent neurodegenerative disease, which creates a significant public health burden. There is a challenge for the optimization of therapies since patients not only respond differently to current treatment options but also develop different side effects to the treatment. Genetic variability in the human genome can serve as a biomarker for the metabolism,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Catechol O-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Agonists

Share to Levodopa

Share to Parkinson Disease

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 34281267
DOI: 10.3390/ijms22137213
PMCID: PMC8268929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?PMID 34281267Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Anti-Parkinson's disease drugs and pharmacogenetic considerationsSemantic proximity Read ↗

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic StudiesSemantic proximity Read ↗

Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.Semantic proximity Read ↗

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.Semantic proximity Read ↗

Parkinson’s Disease: From Gene–Environment Risk to Precision TherapySemantic proximity Read ↗

The role of pharmacogenomics in the personalization of Parkinson's disease treatment.Semantic proximity Read ↗

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Semantic proximity Read ↗

Precision medicine for Parkinson’s disease: The subtyping challengeSemantic proximity Read ↗

Drug Repurposing for Parkinson’s Disease: A Large-Scale Multi-Cohort StudySemantic proximity Read ↗

Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.